伏立康唑和伊曲康唑对来自西班牙的念珠菌属氟康唑敏感及氟康唑耐药临床分离株的体外活性比较

Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.

作者信息

Cuenca-Estrella M, Díaz-Guerra T M, Mellado E, Monzón A, Rodríguez-Tudela J L

机构信息

Unidad de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

出版信息

Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):432-5. doi: 10.1007/s100960050313.

DOI:10.1007/s100960050313

PMID:10442422

Abstract

The in vitro activity of voriconazole was compared with that of itraconazole against 299 fluconazole-susceptible (MIC < or = 8 microg/ml) and 130 fluconazole-resistant (MIC > or = 16 microg/ml) clinical isolates of Candida spp. An adaptation of the National Committee for Clinical Laboratory Standards reference method was employed for determination of MICs. Voriconazole showed more potent activity than either fluconazole and itraconazole, even against some Candida albicans, Candida glabrata, and Candida krusei isolates resistant to fluconazole. However, for fluconazole-resistant isolates, the MICs of itraconazole and voriconazole were proportionally higher than for fluconazole-susceptible isolates. These data may indicate cross-resistance.

摘要

将伏立康唑的体外活性与伊曲康唑针对299株对氟康唑敏感（MIC≤8微克/毫升）和130株对氟康唑耐药（MIC≥16微克/毫升）的念珠菌属临床分离株的活性进行了比较。采用美国国家临床实验室标准委员会参考方法的一种改良方法来测定最低抑菌浓度（MIC）。伏立康唑表现出比氟康唑和伊曲康唑更强的活性，甚至对一些对氟康唑耐药的白色念珠菌、光滑念珠菌和克柔念珠菌分离株也有效。然而，对于对氟康唑耐药的分离株，伊曲康唑和伏立康唑的MIC比氟康唑敏感分离株相应更高。这些数据可能表明存在交叉耐药性。